Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALPG | P10696 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.40 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29061981 | 1.00 | KMT2A (0.46) | KMT2AALDH1A1LMNASMN1; SMN2ALPG | |
| SCHEMBL10468320 | 0.84 | KMT2A (0.43) | KMT2AALDH1A1LMNASMN1; SMN2ALPG | |
| SCHEMBL11861977 | 0.81 | CCR1 (0.44) | KMT2AALDH1A1LMNASMN1; SMN2ALPG | |
| SCHEMBL954801 | 0.81 | ALDH1A1 (0.41) | KMT2AALDH1A1LMNASMN1; SMN2ESR2 | |
| SCHEMBL29061985 | 0.81 | ALDH1A1 (0.41) | KMT2AALDH1A1LMNASMN1; SMN2ESR2 | |
| SCHEMBL1311187 | 0.80 | CCR1 (0.43) | KMT2AALDH1A1LMNASMN1; SMN2ALPG | |
| SCHEMBL7933533 | 0.79 | ALDH1A1 (0.46) | KMT2AALDH1A1LMNASMN1; SMN2ALPG | |
| SCHEMBL12681811 | 0.79 | ESR1 (0.40) | KMT2AESR2ESR1TDP1FFAR1 | |
| SCHEMBL7099557 | 0.79 | ESR1 (0.63) | KMT2AALDH1A1LMNAESR2ESR1 | |
| SCHEMBL8505408 | 0.79 | ESR2 (0.40) | KMT2AALDH1A1SMN1; SMN2ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655482-B | Preparation method of gamma-aminobutyric acid derivatives | 贵州大学 | 2024-06-04 | — | — | CN | disclosed |
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2024-04-30 | — | — | US | disclosed |
| CN-113896685-B | Indoleamine-2, 3-dioxygenase (IDO) inhibitors | 益方生物科技(上海)股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| CN-116655482-A | Preparation method of gamma-aminobutyric acid derivatives | 贵州大学 | 2023-08-29 | — | — | CN | disclosed |
| EP-3414224-B1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| CN-113896685-A | Indoleamine-2, 3-dioxygenase (IDO) inhibitors | 益方生物科技(上海)股份有限公司 | 2022-01-07 | — | — | CN | disclosed |
| US-8486952-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130178462-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | KMT2A 4529/4885ALDH1A1 1956/4885LMNA 2174/4885 |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | KMT2A 506/4885ALDH1A1 801/4885LMNA 4749/4885 |
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | KMT2A 506/4885ALDH1A1 801/4885LMNA 4749/4885 |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | KMT2A 4694/4885ALDH1A1 1538/4885LMNA 1847/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | KMT2A 4529/4885ALDH1A1 1956/4885LMNA 2174/4885 |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | KMT2A 506/4885ALDH1A1 801/4885LMNA 4749/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | KMT2A 805/4885ALDH1A1 412/4885LMNA 2048/4885 |
| US-20130178462-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | KMT2A 4529/4885ALDH1A1 1956/4885LMNA 2174/4885 |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | KMT2A 4529/4885ALDH1A1 1956/4885LMNA 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.